Phlebotomy resulting in controlled hypovolemia to prevent blood loss in major hepatic resections (PRICE-2): study protocol for a phase 3 randomized controlled trial
Author:
Martel GuillaumeORCID, Lenet Tori, Wherrett Christopher, Carrier François-Martin, Monette Leah, Workneh Aklile, Brousseau Karine, Ruel Monique, Chassé Michaël, Collin Yves, Vandenbroucke-Menu Franck, Hamel-Perreault Élodie, Perreault Michel-Antoine, Park Jeieung, Lim Shirley, Maltais Véronique, Leung Philemon, Gilbert Richard W. D., Segedi Maja, Abou-Khalil Jad, Bertens Kimberly A., Balaa Fady K., Ramsay Tim, Fergusson Dean A.
Abstract
Abstract
Introduction
Blood loss and red blood cell (RBC) transfusion in liver surgery are areas of concern for surgeons, anesthesiologists, and patients alike. While various methods are employed to reduce surgical blood loss, the evidence base surrounding each intervention is limited. Hypovolemic phlebotomy, the removal of whole blood from the patient without volume replacement during liver transection, has been strongly associated with decreased bleeding and RBC transfusion in observational studies. This trial aims to investigate whether hypovolemic phlebotomy is superior to usual care in reducing RBC transfusions in liver resection.
Methods
This study is a double-blind multicenter randomized controlled trial. Adult patients undergoing major hepatic resections for any indication will be randomly allocated in a 1:1 ratio to either hypovolemic phlebotomy and usual care or usual care alone. Exclusion criteria will be minor resections, preoperative hemoglobin <100g/L, renal insufficiency, and other contraindication to hypovolemic phlebotomy. The primary outcome will be the proportion of patients receiving at least one allogeneic RBC transfusion unit within 30 days of the onset of surgery. Secondary outcomes will include transfusion of other allogeneic blood products, blood loss, morbidity, mortality, and intraoperative physiologic parameters. The surgical team will be blinded to the intervention. Randomization will occur on the morning of surgery. The sample size will comprise 440 patients. Enrolment will occur at four Canadian academic liver surgery centers over a 4-year period. Ethics approval will be obtained at participating sites before enrolment.
Discussion
The results of this randomized control trial will provide high-quality evidence regarding the use of hypovolemic phlebotomy in major liver resection and its effects on RBC transfusion. If proven to be effective, this intervention could become standard of care in liver operations internationally and become incorporated within perioperative patient blood management programs.
Trial registration
ClinicalTrials.gov NCT03651154. Registered on August 29 2018.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference68 articles.
1. McColl RJ, Brar B, Ghali WA, Dixon E. Hepatic resection in Canada: rates and geographic variation. Can J Surg. 2009;52:E264–8. 2. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002. https://doi.org/10.1097/01.SLA.0000029003.66466.B3. 3. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases. Ann Surg. 2004. https://doi.org/10.1097/01.sla.0000141195.66155.0c. 4. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013. https://doi.org/10.1097/SLA.0b013e318283a4d1. 5. Sima CS, Jarnagin WR, Fong Y, Elkin E, Fischer M, Wuest D, et al. Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg. 2009. https://doi.org/10.1097/sla.0b013e3181b7fad3.
|
|